LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1% ...

To get an idea of why investors and analysts are excited about Irvine-based Edwards Lifesciences Corp.’s latest heart valve, look to Europe. The company’s Sapien valve, which is inserted via a ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...

Edwards Lifesciences Corp.’s next generation of less-invasive heart valves is making its domestic debut, providing a boost that has extended a monthslong rally for shares of the Irvine-based heart ...

SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and ...

Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...

Medtronic (NYSE:MDT) today announced three-year results from the SMART trial comparing its Evolut heart valve to Edwards' ...